P2.06-13 Poor Nutritional Status Is a Poor Prognostic Factor in Malignant Pleural Mesothelioma

7080 Background: Circulating tumor cell (CTC) is a surrogate of distant metastasis, and our preliminary study suggested that CTC detected by an EpCAM-based immuno-magnetic separation system (“CellSearch”) was a useful clinical marker in the diagnosis of malignant pleural mesothelioma (MPM) (Tanaka F. et al ASCO 2008). Methods: Patients who presented at our institute to receive pleural biopsy with suspicion of MPM were prospectively enrolled. CTCs in 7.5mL of peripheral blood were quantitatively evaluated with the CellSearch system. Results: Among 136 eligible patients, 104 were finally diagnosed with MPM, and 32 were with non-malignant diseases (NM). CTC was positive (CTC≥1) in 32.7% (37/104) of MPM pts, and in 9.4% (3/32) of NM pts (p=0.011). CTC-count was significantly higher in MPM (range, 0-9) than in NM (range, 0-1; p=0.007). According to a ROC curve analysis, the CTC-test provided a significant diagnostic performance in discrimination between MPM and NM (AUC= 0.623; P=0.036). Among MPM pts, CTC-positivity and CTC-count were significantly increased with tumor progression (p=0.026 and p=0.008, respectively). For all MPM pts, there was no significant difference in overall survival between CTC-positive and negative pts. However, in a planned subset analysis, CTC was a significant factor to predict poor prognosis (median survival time, 8.0 months for CTC-positive pts, and 20.3 months for negative pts; p=0.012) in pts with epithelioid-type MPM in which CTC was exclusively positive; a multivariate analysis confirmed that CTC, along with PS, was an independent prognostic factor (HR=2.38; P=0.006). Conclusions: CTC was a significant diagnostic marker in discrimination between MPM and NM. CTC-positivity was a significant and independent prognostic factor to predict a poor prognosis of epithelioid MPM. [Table: see text]

Download Full-text

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study

British Journal of Cancer ◽

10.1038/bjc.2015.9 ◽

2015 ◽

Vol 112 (5) ◽

pp. 783-792 ◽

Cited By ~ 22

Author(s):

B Ghanim ◽

T Klikovits ◽

M A Hoda ◽

G Lang ◽

I Szirtes ◽

...

Keyword(s):

Prognostic Factor ◽

Malignant Pleural Mesothelioma ◽

Multicenter Study ◽

Independent Prognostic Factor ◽

Pleural Mesothelioma ◽

Ki67 Index

Download Full-text

CD74: a new prognostic factor for patients with malignant pleural mesothelioma

British Journal of Cancer ◽

10.1038/bjc.2014.117 ◽

2014 ◽

Vol 110 (8) ◽

pp. 2040-2046 ◽

Cited By ~ 15

Author(s):

C Otterstrom ◽

A Soltermann ◽

I Opitz ◽

E Felley-Bosco ◽

W Weder ◽

...

Keyword(s):

Prognostic Factor ◽

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma

Download Full-text

PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study

Therapeutic Advances in Medical Oncology ◽

10.1177/1758835920962362 ◽

2020 ◽

Vol 12 ◽

pp. 175883592096236

Author(s):

Liu Jin ◽

Weiling Gu ◽

Xueqin Li ◽

Liang Xie ◽

Linhong Wang ◽

...

Keyword(s):

Prognostic Factor ◽

Malignant Pleural Mesothelioma ◽

Meta Analysis ◽

Prognostic Significance ◽

Progression Free Survival ◽

The Cancer Genome Atlas ◽

Cochrane Library ◽

Pleural Mesothelioma ◽

Significant Prognostic Factor ◽

Tcga Dataset

Background: The prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with malignant pleural mesothelioma (MPM) has been controversial according to previous investigations. Therefore, we conducted a meta-analysis to assess the potential prognostic significance of PD-L1 expression in MPM. Methods: PubMed, Embase, Web of Science, Scopus, and the Cochrane Library were thoroughly searched for relevant original articles published before 9 April 2020. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) of overall survival (OS) and progression-free survival (PFS) were calculated. The results of the meta-analysis were verified using The Cancer Genome Atlas (TCGA) dataset. Results: In total 16 studies were included in our meta-analysis. A high PD-L1 expression was associated with a poor OS (HR = 1.53, 95% CI = 1.28–1.83, p < 0.001), but not a grave PFS (HR = 1.07, 95% CI = 0.82–1.39, p = 0.643) in MPM. Furthermore, the PD-L1 expression correlated with the sarcomatoid + biphasic type of MPM (odds ratio = 4.32, 95% CI = 2.16–8.64, p < 0.001). TCGA data indicated that PD-L1 was a significant prognostic factor for OS (HR = 2.069, 95% CI = 1.136–3.769, p = 0.0175), but not for PFS (HR = 1.205, 95% CI = 0.572–2.539, p = 0.624), which was in accordance with the results of the meta-analysis. Conclusion: A high PD-L1 expression is a significant prognostic factor for poor OS of patients with MPM. We therefore suggest that PD-L1 expression levels can be used to predict the clinical outcomes of patients with MPM in the future.

Download Full-text